Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma

Cancer

Volumn 107, Issue 2, 2006, Pages 417-422

  Kushner, Brian H ^a   Budnick, Amy ^a   Kramer, Kim ^a   Modak, Shakeel ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cisplatin; Deafness; Dose intensive therapy; Neuroblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PLATINUM DERIVATIVE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG MEGADOSE; FEMALE; HEARING LOSS; HEARING TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; OTOTOXICITY; PRIORITY JOURNAL; SCORING SYSTEM;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HEARING LOSS; HUMANS; MALE; NEUROBLASTOMA;

EID: 33745812833     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22004     Document Type: Article

References (37)

1. Pearson ADJ, Craft AW, Pinkerton CR, et al. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer. 1992;28A:1654-1659.
2. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000;18:2567-2575.
3. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung N-KV. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22:4888-4892.
4. Villablanca JG, Matthay KK, Swift PS, et al. Phase I trial of carboplatin, etoposide, melphalan and local irradiation (CEM-LI) with purged autologous bone marrow transplantation for children with high-risk neuroblastoma. Med Pediatr Oncol. 1999;33:170. Abstract.
5. Park JR, Slattery J, Gooley T, et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol. 2000;35:719-723.
6. Kushner BH, Cheung N-KV Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transpl. 2001;28:551-556.
7. Metzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago pilot II study. J Clin Oncol. 2002;20:2284-2292.
8. Knight GKR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596.
9. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22:669-674.
10. Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klinische Padiatrie. 2002;214:149-152.
11. Bergeron C, Dubourg L, Chastegner P, et al. Long term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: Results of the SFOP NBL90 study. Pediatr Blood Cancer. 2005;45:32-36.
12. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol/Oncol. 2004;26:649-655.
13. Ruiz L, Golden J, Jaffe N, Robertson R, Wang YM. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum (II). Cancer Res. 1989;49:742-744.
14. Stöhr W, Langer T, Kremers A. Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system. Cancer Invest. 2005;23:201-207.
15. Kretschmar CS, Warren MP, Lavally BL, Dyer S, Tarbell NJ. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol. 1990;8:1191-1198.
16. Cohen BH, Zweidler R Goldwein JW, Molloy J, Packer RJ. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg. 1991;16:292-296.
17. Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol. 1996;26:95-100.
18. Ilveskoski I, Saarinen UM, Wiklund T, et al. Ototoxicity in children with malignant brain tumors treated with the "8-in-1" chemotherapy protocol. Med Pediatr Oncol. 1996;27:26-31.
19. Miettinen S, Laurikainen E, Johansson R, Minn H, Laurell G, Salmi TT. Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol Suppl. 1997;529:90-94.
20. McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr. 1983;102:314-317.
21. Skinner R, Pearson ADJ, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927-931.
22. Weatherly RA, Owens JJ, Catlin FI, Mahoney DH. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:917-924.
23. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: A practical scoring system. Med Pediatr Oncol. 1991;19:295-300.
24. Pasic TR, Dobie RA. Cis-platinum Ototoxicity in children. Laryngoscope. 1991;101:985-991.
25. Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: Short and long-term morbidity. Br J Cancer. 1992;66:S36-S40.
26. Todd NW, Alvarado CS, Brewer DB. Cisplatin in children: Hearing loss correlates with iris and skin pigmentation. J Laryngol Otol. 1995;109:926-929.
27. Berg AL, Spitzer JB, Garvin JH. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109:1806-1814.
28. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754-760.
29. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445-2451.
30. Hayes FA, Green AA, Casper J, Cornet J, Evans WE. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: Response and toxicity. Cancer. 1981;48:1715-1718.
31. Philip T, Ghalie R, Pinkerton R, Zucker JM, Bernard JL, Leverger G, Hartmann O. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: A report from the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1987;5:941-950.
32. Hartmann O, Pinkerton CR, Philip T, Zucker JM, Breatnach F. Very high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988;6:44-50.
33. 2): A report from the LMCE Group. Prog Clin Biol Res. 1988;271:573-582.
34. Kushner BH, Heller G, Kramer K, Cheung N-KV. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer. 2000;89:2122-2130.
35. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successfiol approach-Results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000;18:3819-3828.
36. Buhrer C, Weinel P, Sauter S, Reiter A, Riehm H. Acute onset deafness in a 4-year old girl after a single infusion of cis-platinum. Pediatr Hematol Oncol. 1990;7:145-148.
37. Komune S, Asakima S, Snow JB. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg. 1981;89:275-282.